- 1.
Zouboulis CC, Desai N, Emtestam L et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015; 29: 619–44. [PubMed][CrossRef]
- 2.
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2020; 82: 1045–58. [PubMed][CrossRef]
- 3.
Danielsen K, Tzellos T, Antonsen OH et al. Veileder for behandling av hidradenitis suppurativa i Norge. Oslo: Norsk forening for dermatologi og venerologi, 2019. https://beta.legeforeningen.no/foreningsledd/fagmed/norsk-forening-for-dermatologi-og-venerologi/aktuelt/2019/veileder-for-behandling-av-hidradenitis-suppurativa-i-norge/ Lest 17.12.2019.
- 4.
Hendricks AJ, Hsiao JL, Lowes MA et al. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology 2021; 237: 81–96. [PubMed][CrossRef]
- 5.
Grimstad Ø, Tzellos T, Dufour DN et al. Evaluation of medical and surgical treatments for hidradenitis suppurativa using real-life data from the Scandinavian registry (HISREG). J Eur Acad Dermatol Venereol 2019; 33: 1164–71. [PubMed][CrossRef]
- 6.
Tzellos T, Zouboulis CC. Review of comorbidities of hidradenitis suppurativa: Implications for daily clinical practice. Dermatol Ther (Heidelb) 2020; 10: 63–71. [PubMed][CrossRef]
- 7.
Kimball AB, Okun MM, Williams DA et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 2016; 375: 422–34. [PubMed][CrossRef]
- 8.
Beslutningsforum. Beslutning i beslutningsforum for nye metoder: Adalimumab (Humira). https://nyemetoder.no/metoder/adalimumab-humira Lest 16.12.2019.
- 9.
García-Martínez FJ, Vilarrasa Rull E, Salgado-Boquete L et al. Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study. J Dermatolog Treat 2019; 31: 1–5. [PubMed][CrossRef]
- 10.
Riis PT, Boer J, Prens EP et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series. J Am Acad Dermatol 2016; 75: 1151–5. [PubMed][CrossRef]
- 11.
Fajgenbaum K, Crouse L, Dong L et al. Intralesional triamcinolone may not be beneficial for treating acute hidradenitis suppurativa lesions: A double-blind, randomized, placebo-controlled trial. Dermatol Surg 2020; 46: 685–9. [PubMed][CrossRef]
- 12.
Garelik J, Babbush K, Ghias M et al. Efficacy of high-dose intralesional triamcinolone for hidradenitis suppurativa. Int J Dermatol 2021; 60: 217–21. [PubMed][CrossRef]
- 13.
Salvador-Rodríguez L, Arias-Santiago S, Molina-Leyva A. Ultrasound-assisted intralesional corticosteroid infiltrations for patients with hidradenitis suppurativa. Sci Rep 2020; 10: 13363. [PubMed][CrossRef]
- 14.
Kohorst JJ, Baum CL, Otley CC et al. Surgical management of hidradenitis suppurativa: Outcomes of 590 consecutive patients. Dermatol Surg 2016; 42: 1030–40. [PubMed][CrossRef]
- 15.
Blok JL, Boersma M, Terra JB et al. Surgery under general anaesthesia in severe hidradenitis suppurativa: a study of 363 primary operations in 113 patients. J Eur Acad Dermatol Venereol 2015; 29: 1590–7. [PubMed][CrossRef]
- 16.
Dahmen RA, Gkalpakiotis S, Mardesicova L et al. Deroofing followed by thorough sinus tract excision: a modified surgical approach for hidradenitis suppurativa. J Dtsch Dermatol Ges 2019; 17: 698–702. [PubMed][CrossRef]
- 17.
van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 2010; 63: 475–80. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.